A multicenter European cohort study demonstrates that antifungal treatment significantly reduces 60-day mortality in COVID-19-associated pulmonary aspergillosis (CAPA), particularly in immunocompromised patients. Key findings underscore the urgency of CAPA screening and targeted therapy in critical care settings.